"Novartis' Fabhalta® Shows Promise in Treating Rare Kidney Disease: Positive Phase III Results Announced"
Published: 2024-05-25Novartis has made a big step in fighting rare kidney diseases. They shared good news from their Phase III APPEAR-C3G study for Fabhalta® (iptacopan) at the ERA Congress. The study showed a 35.1% drop in proteinuria and better kidney function (eGFR) over six months compared to a placebo. This is great news for people with C3 glomerulopathy (C3G), a rare kidney disease that can lead to kidney failure in about ten years.
Fabhalta is a pill that targets the root cause of C3G. This is a big advance in treating this serious disease. The study showed that Fabhalta works well and is safe, with no new safety issues.
Novartis plans to ask for approval of Fabhalta in late 2024. If approved, it could soon be available for patients. The study will continue for another six months, and more results will be shared at future medical meetings.
This progress shows how important it is to share information in the medical field. When researchers share data, others can study it and find new ways to help patients.
People should know that sharing data can build trust. When companies share their data openly, others can check it. This makes people trust the companies more because they can see the proof behind the claims.
For example, Novartis shared the results of the Fabhalta study, which helps build trust in the drug’s safety and effectiveness. This openness can make people feel more confident about the drug.
Another example is the European Medicines Agency (EMA), which shares clinical trial data with the public. This helps researchers find new insights and better treatments. People generally see these efforts as good, as they show a commitment to safety and accountability.
Knowing about these practices helps people make better health decisions. By understanding how companies share data, consumers can find reliable information and avoid false claims.
Stay updated as we continue to follow the progress of Fabhalta and other new treatments. Together, we can use the power of transparency to create a healthier future for everyone.
https://www.prnewswire.com/news-releases/novartis-presents-latest-phase-iii-fabhalta-iptacopan-data-in-c3-glomerulopathy-c3g-showing-clinically-meaningful-and-statistically-significant-35-1-proteinuria-reduction-vs-placebo-302155372.html